Correction to: White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab

被引：0
|
作者：
Fayez Estephan
Xiaobu Ye
Omar Dzaye
Nina Wagner-Johnston
Lode Swinnen
Douglas E. Gladstone
Rich Ambinder
David Olayinka Kamson
Sebastian Lambrecht
Stuart A. Grossman
Doris D. M. Lin
Matthias Holdhoff
机构：
[1] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Department of Neurosurgery
[2] Johns Hopkins University School of Medicine,Russell H. Morgan Department of Radiology and Radiological Science
[3] Johns Hopkins University School of Medicine,Department of Radiology and Neuroradiology
[4] Charité,Division of Neuroradiology, Russell H. Morgan Department of Radiology and Radiological Science
[5] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[6] Johns Hopkins University School of Medicine,undefined
来源：
Journal of Neuro-Oncology | 2019年 / 145卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The following discrepancies and errors were found in the original publication:
引用
收藏
页码：467 / 467
相关论文
共 50 条
  • [31] High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma
    Freeman, Tracelyn
    Legasto, Carlo S.
    Schickli, M. Alexandra
    McLaughlin, Eric M.
    Giglio, Pierre
    Puduvalli, Vinay
    Gonzalez, Javier
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [32] Outcome after High-dose Methotrexate and Radiotherapy in Primary Central Nervous System Lymphoma
    Choi, J.
    Kim, I.
    Heo, D.
    Jung, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S254 - S254
  • [33] Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma
    Sun, Kai
    Tao, Hongwei
    Ding, Tianling
    Li, Ziran
    Qiu, Xiaoyan
    Zhong, Mingkang
    Wu, Zhuo
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (12) : 2196 - 2204
  • [34] Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab
    Larouche, Jean-Francois
    Bergeron, Marc
    Hampson, Grace
    Illidge, Tim
    Delage, Robert
    BLOOD, 2011, 118 (21) : 714 - 714
  • [35] High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma
    Holdhoff, Matthias
    Ambady, Prakash
    Abdelaziz, Ahmed
    Sarai, Guneet
    Bonekamp, David
    Blakeley, Jaishri
    Grossman, Stuart A.
    Ye, Xiaobu
    NEUROLOGY, 2014, 83 (03) : 235 - 239
  • [36] HIGH-DOSE METHOTREXATE WITH OR WITHOUT RITUXIMAB IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA
    Chamberlain, Marc C.
    NEUROLOGY, 2015, 84 (07) : 758 - 759
  • [37] Long Term Outcomes of Rituximab, Temozolamide, and High-Dose Methotrexate for Lymphoma Involving the Central Nervous System
    Nagle, Sarah Jordan
    Shah, Nirav N.
    Ganetsky, Alex
    Landsburg, Daniel J.
    Nasta, Sunita Dwivedy
    Mato, Anthony
    Schuster, Stephen J.
    Tsai, Donald Edward
    Svoboda, Jakub
    BLOOD, 2015, 126 (23)
  • [38] Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.
    Lindhorst, Scott Michael
    McSherry, Frances
    Desjardins, Annick
    Friedman, Henry S.
    Peters, Katherine B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?
    Dalia, Samir
    Price, Samantha
    Forsyth, Peter
    Sokol, Lubomir
    Jaglal, Michael
    LEUKEMIA & LYMPHOMA, 2015, 56 (02) : 500 - 502
  • [40] Phase II trial of high-dose intravenous methotrexate (MTX) and rituximab with or without intraventricular DepoCyt in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)
    Fisher, Rebecca
    Glantz, Michael
    Blumenthal, Deborah
    Batten, Julia
    Van Horn, Alixis
    Chalmers, Lisa
    Chamberlain, Marc
    NEURO-ONCOLOGY, 2006, 8 (04) : 441 - 441
12345